Companies · Other Health Care

Phoenix Life Sciences International Limited.

DENVER · Other Health Care

Diligence memoA one-page analyst read on Phoenix Life Sciences International Limited. — recommendation, valuation, rhythm, risks.
$40.9M
Total raised · real
2
Rounds
45.5×
Latest step-up
Top 10%
Sector rank · raised
Series C
Latest stage · inferred · Mon Jul 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Phoenix Life Sciences International Limited. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.79× the median modeled value of Series C Other Health Care companies in 2019–2021 (46 peers) — value vs value, same stage and era.
  • Within the normal band (79% of peer median) for its niche.
Dormant
  • Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Phoenix Life Sciences International Limited. is one of 5376 Other Health Care companies tracked from DENVER. By capital raised it ranks among the largest (ahead of 91% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$0–$1M
Issuer revenue
Rule 506(c)
Reg D exemption
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2018-07-01 Raised $100M (real) Modeled valuation $2.3B (est)$100M$2.3BSeries C2018Series C · 2018-11-01 Raised $880K (real) Modeled valuation $20M (est)$880K$20MSeries C2018Series C · 2019-07-01 Raised $40M (real) Modeled valuation $915M (est)$40M$915MSeries C2019+$880K+$40MCumulative $141M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$100.0M · 2018
Series C extension$880K · 2018
Series C extension$40.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.

Modeled valuation trajectory
$914.5M
Base estimate est.
$145.4M
Conservative case
$2.4B
Upside case
$266.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series C · modeled $2.3B · 2018-07-012018Series C · modeled $20.1M · 2018-11-01Series C · modeled $914.5M · 2019-07-012019
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
7.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$40.9M/yr
Capital velocity
8.0 yr
On record since
2018
First round
3
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 17× above median
This company$40.9M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.9× of median
This company$40.0M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 41× above median
This company$914.5M
Sector median$22.1M

Raised more than 91% of sector peers (real $). Modeled value above 96% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #35 of 46.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Avail Medsystems, Inc. · Series C Raised $126.7M · modeled $2.2B (est)Whoop, Inc. · Series C Raised $180.4M · modeled $2.1B (est)HRGi Holdings, Inc. · Series C Raised $91.2M · modeled $2.1B (est)Ambulnz, Inc. · Series C Raised $90.0M · modeled $2.1B (est)MedAvail, Inc. · Series C Raised $97.0M · modeled $2.0B (est)SOC Telemed, Inc. · Series C Raised $103.0M · modeled $1.9B (est)Eargo, Inc. · Series C Raised $187.4M · modeled $1.8B (est)Truth Holdings, L.P. · Series C Raised $88.8M · modeled $1.6B (est)NeuroPace Inc · Series C Raised $208.6M · modeled $1.5B (est)DermTech, Inc. · Series C Raised $98.9M · modeled $1.5B (est)Mydna, Inc · Series C Raised $72.1M · modeled $1.4B (est)Ancora Heart, Inc. · Series C Raised $151.3M · modeled $1.4B (est)Phoenix Life Sciences International Limited. (this company) Raised $40.9M · modeled $914.5M (est)Phoenix Life Sciences International Limited.
CompanyStageRaised · realValue · estvs peer med.
Avail Medsystems, Inc.Series C$126.7M$2.2B1.87×
Whoop, Inc.Series C$180.4M$2.1B1.81×
HRGi Holdings, Inc.Series C$91.2M$2.1B1.81×
Ambulnz, Inc.Series C$90.0M$2.1B1.79×
MedAvail, Inc.Series C$97.0M$2.0B1.75×
SOC Telemed, Inc.Series C$103.0M$1.9B1.65×
Eargo, Inc.Series C$187.4M$1.8B1.61×
Truth Holdings, L.P.Series C$88.8M$1.6B1.43×
NeuroPace IncSeries C$208.6M$1.5B1.33×
DermTech, Inc.Series C$98.9M$1.5B1.29×
Mydna, IncSeries C$72.1M$1.4B1.26×
Ancora Heart, Inc.Series C$151.3M$1.4B1.24×
Phoenix Life Sciences International Limited. this companySeries C$40.9M$914.5M0.79×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$100.0M2018-07-01$666.7M$2.3B90%
Series C$880K2018-11-01$5.9M$20.1M90%
Series C$40.0M2019-07-01$266.7M$914.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$100.0M2018-07-01
    • First recorded raise — entered as Series C.
  2. Series C$880K2018-11-01
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 113.7× smaller than the prior — bridge or down round.
  3. Series C$40.0M2019-07-01
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 45.5× larger than the prior — scaling up.
    • Switched to Rule 506(c) (was Rule 506(b)).
Intelligence
2019 ~Q4
Modeled next raise · ~6mo cadence
$120.0M
Modeled next size est.range $78.0M$192.0M
45.5×
Last step-up
$40.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Martin Henry Tindall2018-07
Registry & provenance

Phoenix Life Sciences International Limited. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1493212
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
AHS VenturesOther Health CareSeries C$41.0M$404.9Msame sector · same stage
USHW Holdings CorpOther Health CareSeries C$40.5M$925.9Msame sector · same stage
Nuvasive IncOther Health CareSeries C$40.5M$925.1Msame sector · same stage
Cloudbreak Health, LLCOther Health CareSeries C$40.2M$918.5Msame sector · same stage
Fresenius Medical Care Lake County, LLCOther Health CareSeries C$40.0M$915.3Msame sector · same stage
PhyMed Holdings, LLCOther Health CareSeries C$42.0M$960.2Msame sector · same stage
PTSH Holdings, LLCOther Health CareSeries C$42.3M$967.1Msame sector · same stage
Sees Holdings, LlcOther Health CareSeries C$43.6M$996.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TMRW Life Sciences Holdings, LLCOther Health CareSeries A$242.2M83%
Alter Life Sciences LLCOther Health CarePre-Seed$2.0M83%
Botany Scientifics LLCOther Health CarePre-Seed$1.4M82%
UE LifeSciences Inc.Other Health CarePre-Seed$7.5M82%
Zyus Life Sciences Inc.Other Health CareSeries B$10.4M82%
Phoenix Technology Group Inc.Software / TechPre-Seed$29.3M82%
LexaGene Life Sciences RD Investors, LLCOther Health CareSeries A$53.2M81%
TMRW Life Sciences, Inc.Other Health CareSeries D+$284.0M81%
Frequently asked
How much funding has Phoenix Life Sciences International Limited. raised?
Phoenix Life Sciences International Limited. has raised approximately $40.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Phoenix Life Sciences International Limited.'s estimated valuation?
Provath's modeled valuation for Phoenix Life Sciences International Limited. is approximately $914.5M (modeled range $145.4M–$2.4B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Phoenix Life Sciences International Limited. at?
Phoenix Life Sciences International Limited.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Mon Jul 01.
What does Phoenix Life Sciences International Limited. do and where is it based?
Phoenix Life Sciences International Limited. operates in the Other Health Care sector, based in DENVER.
Explore related

See where Phoenix Life Sciences International Limited. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Phoenix Life Sciences International Limited., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.